To provide an improved type humanized immunoglobulin which is substantially nonimmunogenic to human, easily and economically producible in a form suitable for application to a therapeutic agent, etc. , and to provide a therapeutic composition for treatment using the same.
The invention relates to a method for preparation of the humanized immunoglobulin exhibiting a binding affinity to the antigen of about 108M-1 or stronger, and having framework regions originating from light and heavy chains of human receptor immunoglobulins and complementarity determining regions (CDR), defined by Kabat, et al., from a donor immunoglobulin. The method includes steps of substituting at least one non CDR framework amino acids of the acceptor immunoglobulin with a corresponding amino acid originating from the donor immunoglobulin at a position in the immunoglobulins.
SELICK HAROLD E
Takaaki Yasumura
Natsuki Morishita
Next Patent: FUSION PROTEIN COMPOSED OF LIGAND BONDED PROTEIN AND STABLE PLASMA PROTEIN